Junshi Biosciences' application for the new drug Rocabutuzumab injection has been accepted
Junshi Biosciences (01877.HK) announced that it has received notification from the National Medical Products Administration that the company's product, Rocaquibab Injection (recombinant humanized anti-IL-17A monoclonal antibody injection, product code: JS005), has had its new drug application accepted for the treatment of adult patients with moderate to severe plaque psoriasis suitable for systemic therapy or phototherapy.
In addition to this new drug application, all participants in the Phase II clinical study of Rocaquibab for the treatment of active ankylosing spondylitis have completed treatment and entered the safety follow-up period
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments